Join the Chronic Spasticity group to help and get support from people like you.
Chronic Spasticity News (Page 2)
First Biosimilar, Tyruko, Approved to Treat Multiple Sclerosis
FRIDAY, Aug. 25, 2023 – The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of...
Patients Say Ketogenic Diet Aids Multiple Sclerosis Symptoms
MONDAY, Aug. 21, 2023 – Patients report that a ketogenic diet (KD) improves multiple sclerosis (MS) symptoms, according to a study published in the August issue of Clinical Nutrition. Emma Wetmore,...
2001 to 2020 Saw Shift in Rx for Disease-Modifying Therapy for Multiple Sclerosis
THURSDAY, July 27, 2023 – Oral disease-modifying therapies (DMTs) predominated new initiations for treatment of multiple sclerosis (MS) in 2020, according to a study published online July 10 in JAMA...
Early Treatment of Demyelination Events Cuts Long-Term Disability in MS
THURSDAY, July 20, 2023 – For multiple sclerosis patients with a first demyelinating event, earlier treatment initiation is associated with a reduction in the risk for long-term disability,...
Genes Identified in Association With Multiple Sclerosis Severity
FRIDAY, July 7, 2023 – Authors of a study published online June 28 in Nature have identified genetic markers associated with multiple sclerosis (MS) severity. Adil Harroud, M.D., from the University...
FDA Approves Expanded Botox (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity
NORTH CHICAGO, Ill., July 9, 2020 /PRNewswire/ – Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License...
FDA Approves Movement Disorder Drug from CNS Therapeutics: Gablofen (Baclofen Injection) for the Treatment of Severe Spasticity
ST. PAUL, Minn.--(BUSINESS WIRE)--Nov 23, 2010 - Today, CNS Therapeutics announced the FDA approval of Gablofen (baclofen injection) for use in the management of severe spasticity, giving healthcare...
Botox (onabotulinumtoxinA) Receives FDA Approval for Treatment of Upper Limb Spasticity in Adults
IRVINE, Calif.--(BUSINESS WIRE)--Mar 10, 2010 - Allergan, Inc. today announced that the United States Food and Drug Administration (FDA) has approved Botox (onabotulinumtoxinA) for the treatment of...
Ask a question
To post your own question to this support group, sign in or create an account.